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Abstract
Immersive, interactive and mHealth technologies are increasingly being used in clinical research, healthcare and reha-
bilitation solutions. Leveraging technology solutions to derive new and novel clinical outcome measures is important to
the ongoing assessment of clinical interventions. While demonstrating statistically significant changes is an important
element of intervention assessment, understanding whether changes detected reflect changes of a magnitude that are
considered meaningful to patients is equally important. We describe methodologies used to determine meaningful
change and recommend that these techniques are routinely included in the development and testing of clinical assess-
ment and rehabilitation technology solutions.
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Introduction
Miniaturisation of sensors and circuitry has given rise
to huge proliferation in the development and commer-
cialisation of wearable and sensor-based technologies
with application to health and wellness. Much research
and development activity has involved the application
of interactive and immersive technologies in the areas
of healthcare and rehabilitation. Immersive technolo-
gies are those that merge the physical world and the
digital or simulated world, thereby creating a sense of
immersion, such as virtual reality (VR) applications. In
healthcare, VR systems, for example, have shown
promise in improving outcomes such as muscle bal-
ance, dexterity and grip in comparison to traditional
rehabilitation in upper limb rehabilitation after spinal
cord injury,1 and to improve the emotional health of
cancer patients and decrease associated disease-related
psychological symptoms.2 Applications using motion-
based gaming platform technology, in particular using
the Microsoft KinectVR (Microsoft Corp., Redmond,
Washington, USA), have been reported to provide
therapeutic benefits in areas such as stroke,3
Parkinson’s disease,4,5 multiple sclerosis6 and cerebral
palsy.7 Mobile Health (mHealth – the use of mobile
and wireless devices to improve health outcomes,
healthcare services and health research8) solutions
have, for example, been reported to improve outcomes
such as working memory, concentration and interfer-
ence processing in children suffering from attention-
deficit hyperactivity disorder.9
In addition to providing the basis for new treatment
interventions, interactive technologies are being utilised
to develop new ways to measure health outcomes in
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clinical research. This enables researchers to track and
monitor changes in health status over time or resulting
from treatments such as the application of new phar-
maceutical products. For example, the Microsoft
Kinect has been used to measure performance-based
health outcomes such as measures of gait and balance
in indications including multiple sclerosis,10,11 stroke12
and Parkinson’s disease,4 and measures of upper
extremity range of motion in adhesive capsulitis13 and
stroke.14 mHealth applications, in particular those
leveraging the inbuilt sensors and components of
modern smartphones, have been used to measure new
and novel health outcomes in a variety of indications,
speeded by the availability of platforms such as Apple
ResearchKit and Google StudyKit. For example,
Roche Pharmaceuticals (Basel, Switzerland) has devel-
oped an innovative mHealth platform and app that
enables the measurement of a number of health out-
comes via active performance tests conducted by the
patient. These leverage Android smartphone compo-
nents including the accelerometer, gyroscope and
touchscreen.15 Roche have recently implemented this
application to study phonation, tremor, balance, gait
and dexterity in Parkinson’s disease clinical trials.16
Over the past two decades, clinical drug develop-
ment programmes have become increasingly complex
and have included a greater volume and variety of
assessments and clinical procedures. In particular,
there has been increased interest and uptake in the
use of new technologies, including gaming platforms
and sensor-based solutions to provide richer informa-
tion on the efficacy and safety of new potential medi-
cations. Pfizer (New York, NY), for example, has
recently reported positive results from a study evaluat-
ing the measures of multitasking and interference proc-
essing performance collected while using the Project:
EVO videogame (Akili Interactive Labs, Boston,
MA) as biomarkers to enable the selection and longi-
tudinal assessment of Alzheimer’s patients.17 Clinical
drug developers are also seeking to understand how
to leverage other interactive technologies to measure
and track intervention effects, including (for example)
wearable sensors, motion-based gaming platforms and
VR applications.
Healthcare solutions, clinical research and clinical
trials rely upon robust and validated methodologies
to measure health status and to detect treatment-
related changes over time. This enables the efficacy
and safety of new interventions to be accurately
assessed and measured. In some cases, these evalua-
tions rely upon subjective assessments by the investiga-
tor or the patient, such as patient-reported outcome
measures (PROMs) and clinician-reported outcomes
(ClinROs). While important, in some instances these
subjective measures may not be sensitive enough to
detect treatment-related changes and may be unable
to conclusively demonstrate treatment effects when
they exist. Clinical trials using subjective clinician
assessments often must include comprehensive rater
training to limit the effects of intra- and inter-rater var-
iability affecting the sensitivity of endpoints mea-
sured.18 For example, a primary reason suggested for
the inability to detect differences between treatment
groups in a large multinational trial of fluoxetine com-
pared to placebo in geriatric depression was the vari-
ability between raters in the subjectively assessed
ClinRO used as the primary endpoint.19 Leveraging
mHealth and interactive technologies may provide an
opportunity to supplement treatment evaluations with
new, novel and objective health outcome measures that
may permit increased precision to detect treatment
effects and/or enable the measurement of constructs
not previously possible. Understanding the clinical rel-
evance of changes detected is of vital importance to
understand if an intervention is producing the magni-
tude of change that will be seen to impact patients.
This applies both to the use of interactive technologies
to measure intervention effects and the understanding
of effects of using interactive technologies when they
are intended as an intervention.
In this article, we explore a recommended approach
to defining meaningful change in new health outcome
measures. This is an element that is largely overlooked
in the development and assessment of immersive,
interactive and mHealth technologies developed as
interventions and technologies to measure health
status. We recommend that this becomes a component
of rehabilitation and clinical assessment solution devel-
opment and testing when using immersive, interactive,
wearable and mHealth technologies.
Clinical outcomes and endpoints
Clinical outcomes are measurable characteristics influ-
enced by an individual’s baseline state or an interven-
tion.20 These might include estimates of functional
reaching volumes within immersive game-driven
applications, free-living activity measurements using
an accelerometer or dexterity measures using an
mHealth tapping test on a mobile phone. Outcome
assessments are used to define efficacy endpoints
when developing a therapy for a disease or condition.
Interactive and mHealth technologies have the poten-
tial to produce many possible clinical outcome meas-
ures, and determining those important in measuring
pertinent aspects of health status that are important
to the patient or condition studied is essential.
A clinical endpoint is defined as: “A characteristic or
variable that reflects how a patient feels, functions, or
survives”.21 Endpoint descriptions should also include
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a definition of how and when they are measured, how
they are calculated from outcome data, rules for miss-
ing data and how they should be analysed. For exam-
ple, an endpoint derived from the outcome data
collected using a wearable continuous glucose monitor
may be the change from baseline in mean daily time
within target range measured over a seven-day interval
after 12 weeks of treatment.
In regulatory clinical trials, an endpoint model is
required to be defined within the study protocol and
regulatory submission materials. This model will detail
each study concept of interest, and identify how the
endpoints selected relate to each concept, and indicate
which endpoints are primary (that the study is powered
to adequately assess), secondary and exploratory.
Understanding how to interpret changes measured in
study endpoints is an important component of the
assessment of any intervention, whether a pharmaceu-
tical treatment or a healthcare/rehabilitation solution.
Interpretability
Meaningful change
Meaningful change can be considered to represent the
smallest difference in an endpoint measure that would
be perceived by patients as beneficial. For many new
and novel endpoints derived from the new application
of technologies, this understanding of meaningful
change thresholds may not already exist. It will be
important to assess this if the approach is to be used
to measure and monitor changes in health outcomes.
In this section on interpretability, we use the illustra-
tion of a clinical endpoint measuring activity derived
from the output of a wearable step-counting device, as
very few published examples exploring meaningful
change for other mHealth and interactive technology
solutions exist.
Meaningful change is likely to be different between
patient populations. For example, in an mHealth inter-
vention measuring and encouraging stepping activity,
measures of meaningful change in the number of steps
walked per day are likely to be lower in less active
patient populations such as those suffering from chron-
ic obstructive respiratory disease (COPD) compared to
more active groups, such as type 1 diabetics, where the
average number of steps per day has been reported to
be 2237 and 8008 steps/day, respectively.22
While the importance of statistical significance in
demonstrating the effects of an intervention is unques-
tioned, it is also important to recognise that effect sizes
detected through statistical tests may be of insufficient
magnitude to be considered relevant to the patient.
Understanding the threshold for meaningful change
(also referred to as clinically relevant change) is
important when interpreting any statistically significant
effect sizes detected.
This meaningful change may be represented by the
clinically important difference (CID), also called the
minimal important difference (MID) or the minimally
clinically important difference (MCID), or by the min-
imal individual change that distinguishes a responder
(an individual exhibiting a meaningful improvement)
from a non-responder. The CID/MID/MCID repre-
sents the minimum change in group means considered
clinically relevant, whereas the individual responder
definition represents the magnitude of individual
change considered clinically relevant.
In general, the responder definition is useful in inter-
preting the results at an individual patient level, for
example, by determining the proportion of patients
that achieved the defined responder definition. This is
arguably easier to interpret than an effect size resulting
from an analysis of group mean differences. However,
on account of the loss of information associated with
converting a continuous measure to a binary outcome,
and the associated loss of statistical power,23,24 the
analysis of group mean changes in outcome measures
derived from interactive and mHealth technologies in
clinical trials remains important. Responder analyses
typically provide helpful complementary context and
interpretation. The analysis of group mean differences
will also typically drive clinical intervention study
power calculations where it is appropriate to power
studies based on this endpoint.
The MCID and responder definition of change pro-
vide similar but not identical values: the MCID is
defined in terms of differences in mean scores, whereas
a responder definition is considered by evaluating indi-
vidual changes. The responder definition could there-
fore be larger or smaller than the MCID depending on
the degree of change considered. It is recommended
that when identifying the amount of change that is
meaningful to patients, researchers should aim to esti-
mate both the MCID and one or more individual
responder definitions. Both of these provide useful
information in terms of both study design and
interpretation.
Measuring meaningful change
There are a number of approaches that have been
reported with which to demonstrate the clinical rele-
vance of change observed with an outcome measure.
These include consensus-based, anchor-based and
distribution-based methods, as described below.
Consensus-based methods. Consensus-based methods uti-
lise an expert panel of clinical and domain experts to
define a threshold for clinically relevant change in the
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specific patient population to be studied. Typically,
consensus approaches use techniques such as Delphi
methods that operate in an iterative manner. Using
Delphi methods, each panel member provides an initial
estimate of the MCID along with the rationale guiding
their choice. Panel members then review all estimates
and explanations, via a blinded summary provided by a
facilitator, and are encouraged to revise their estimates
based on the responses of other panel members.
Iterating this process typically results in a consensus
value being reached.
This approach, while helpful in obtaining agreement
on the clinical relevance of an endpoint per se, may be
less able to determine the true meaning of changes
observed. Consensus approaches typically assume
that clinicians and health professionals are able to
determine the magnitude of change that is important
to a patient. The FDA in their draft guidance on
patient-focussed drug development state that
“Patients are experts in their own experience of their
disease or condition”,25 and so ultimately the relevance
of changes in health status experienced should be deter-
mined by the patient. For these reasons, where possi-
ble, consensus methods should not be solely relied
upon to estimate the MCID or responder definition
for clinical data interpretation.
Distribution-based methods. Distribution-based methods
leverage understanding of the distribution of the out-
come measure recorded to identify the magnitude of
change that would be unlikely to be observed by
chance alone. It is common to use more than a single
distributional method to obtain a consensus or range
for the MCID value. A number of distributional meth-
ods exist including the standard error of measurement
(SEM), empirical rule effect size, Cohen’s effect size
and 0.5 baseline standard deviation (see Demeyer
et al.26 for example, Table 1). It should be noted that
distribution-based methods of estimating MCID and
responder definition can often be less able to determine
robust estimates when sample sizes are small or when
there is large variability of data at baseline.
Despite their inherent simplicity, distribution-based
methods, however, fail to associate statistical changes
with whether a truly meaningful change has occurred.
Along with other authors (e.g. McLeod et al.27), we
agree that distribution-based methods should be consid-
ered supportive to anchor-based methods (see below) as
opposed to providing primary measures of MCID and
responder definitions. However, in some circumstances,
anchor-based approaches may not be possible due to the
lack of a suitable anchor measure, and it may be neces-
sary to rely more heavily on this approach.
A good example of determining meaningful change
using wearable technology to measure physical activity
levels is reported by Demeyer et al.26 They used
distribution-based methods to estimate the MCID in
total daily steps recorded using an accelerometer
amongst COPD patients after pulmonary rehabilita-
tion. They reported the MCID in this population as
between 600 and 1100 steps/day based on the range
of values obtained using a variety of distribution-
based methods (Table 1). While these values may be
high when compared to the average steps per day
achieved amongst COPD patients reported elsewhere,
estimated to be 2237 steps/day,22 the clinical impor-
tance of improvements of at least 600 steps/day
was further demonstrated by reduced risk for hospital
re-admission for patients achieving this activity
improvement threshold.
Anchor-based methods. Anchor-based methods compare
endpoint measures obtained using the new technology
to an anchor that is itself interpretable in having known
relevance to patients.28 Anchors must be simple and
measure a concept that is directly associated with the
outcome measure under evaluation. In addition, when
designing a study to estimate meaningful change it will
be important to select an intervention and time period
for which a change in the anchor measure is expected.
It is possible that anchors may be objective measures
using other related instrumented approaches, or they
may be based on subjective assessments made by the
patient or clinician. For example, if we wish to deter-
mine the meaningful change in an outcome measure of
dexterity, collected using a tapping test delivered using
an mHealth application on a smartphone, an objective
anchor measure may be the count of finger to thumb
taps achieved in a 30-s interval during an in-clinic per-
formance test. Subjective anchors, on the other
hand, might be a clinician-rating using the 0 to 4
scale for finger tapping assessment in the Unified
Parkinson’s Disease Rating Scale, or a global patient
impression of change score where the patient is
asked to rate any perceived change in bradykinesia





SEM SD Baseline (1 – ICC) 599
Empirical rule
effect size
0.08 6 SDD 1029
Cohen’s effect size 0.5 SDD 1072
0.5 SD 0.5 SDBaseline 1131
SEM: standard error of measurement; MCID: minimally clinically impor-
tant difference; ICC: intraclass correlation coefficient; SD: standard
deviation.
Reproduced from Demeyer et al.26
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(slowness of movement). To be applicable, meaningful
change in the anchor measure must be understood, and
changes observed in the anchor measure must be at
least moderately associated with changes in the new
outcome measure. This association may be assessed
by Pearson or Spearman correlations, or more simply
via visual inspection of trends. Because associations are
typically modest, and anchors may be measuring slight-
ly different concepts, researchers typically include a
range of anchor measures to enable a range or consen-
sus value to be derived.
Anchor-based methods can be used to define the
MCID for group mean changes or individual respond-
er definitions. As the interpretability of the anchor is
known, it is possible to define an anchor value, or range
of anchor values, that represent the minimally impor-
tant group mean change or an individual change indic-
ative of a responder. In each case, by collecting both
the new outcome measure and the anchor values in a
suitable intervention study in which change is expected,
the corresponding MCID and responder definition of
the target outcome measure can be estimated.
When determining the MCID using anchor-based
methods, it is usual to define a value, or a range of
values, for the anchor measure that correspond to the
MCID and then calculate the target score that corre-
sponds to that value.28 An example is reported by
Motl et al.29 In their study, patients with multiple scle-
rosis were provided with a wearable accelerometer to
measure daily steps over a seven-day period. The study
included a number of subjective PROMs as anchor
measures including the Multiple Sclerosis Walking
Scale (MSWS-12) and the Patient-Determined Disease
Steps (PDDS) scale. Meaningful change in both meas-
ures is well understood. A 10-point change in the total
score of the MSWS-12 instrument and a 1-point change
in the PDDS are considered to be the smallest changes
deemed meaningful to the patient. Relating changes in
steps/day observed to the anchor values collected, the
authors reported MCID estimates of 642 and 915 steps/
day for the two anchor comparisons, respectively.
Figure 1 presents the anchor-based MCID assessment
resulting from the MWSW-12 analysis. While a trend is
evident, this is a good illustration of the need for multi-
ple anchors to be examined in the same study to enable
the MCID to be triangulated – as the between-subject
variability in the relationship between the anchor and
the new measure is often high, as in this case.
The most common approach to determine an individ-
ual responder definition is to classify responders based
upon the anchor definition, and then use receiver oper-
ating characteristic curves to determine the optimal cut-
off point for the target measure to define a responder,
based on minimising responder misclassification (see
Ward et al.30 and Deyo and Centor31 for example).
It is acknowledged that in some cases suitable
anchor measures cannot be determined. For example,
despite attempting to derive the MCID for total daily
steps in COPD patients from anchors based on the 6-
minute walking test distance and Chronic Respiratory
Disease Questionnaire (CRDQ) scores, Demeyer
et al.26 reported that this was not possible in their eval-
uation as these measures were found to be only poorly
correlated with the total daily steps measurements. In
this case, they relied upon distribution-based methods
to evaluate the MCID.
Incorporation within product
development
Defining meaningful change should be a component of
development activities when creating applications using
immersive, interactive and mHealth technologies to
assess clinical outcomes in clinical research. In addition,
defining pertinent clinical outcomes that can be auto-
matically calculated during the use of rehabilitation
applications, and their associated values of meaningful
change, should be a component of the development and
testing of rehabilitation applications. For example, when
developing an application to assist patients in the correct
and regular conduct of a rehabilitation exercise regimen,
technologies such as Microsoft Kinect also enable the
accurate tracking of joint coordinates and movements
which can be the basis of objective outcome measures
defining, for example, joint ranges of motion. These out-
come measures can be used to define clinical endpoints
that can be tracked over time, and the MCID or
responder definition of these new endpoints should be
understood. The minimal meaningful change can also be
important to understand when defining an acceptance
region for equivalence studies, for example comparing
Figure 1. Association between anchor measure (MSWS-12
score) and endpoint derived from wearable device (steps/day).
This chart was redrawn from Motl et al.29
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the results of a new approach to that of a gold standard
or predicate device.
Studies to assess the use of these technologies should
include the incorporation of relevant anchor measures.
This has the benefit of providing an additional
demonstration of intervention effect in addition to pro-
viding the means to assess meaningful change in
the outcomes derived from the new technology, in the
ways described above.
Where it is difficult to determine suitable anchor
measures, the use of a patient global impression of
severity (PGI-S) or change (PGI-C) scale might be sen-
sible; where a one-point change in PGI-S from baseline
would represent a minimal individual change that is
meaningful, a score other than “No change” is mean-
ingful on the PGI-C (Figure 2).
This methodology will enable greater understanding
of the value and interpretation of new and novel end-
points derived from new technologies and provide
interpretation to effect sizes observed during rehabili-
tation application assessment.
Conclusions
Meaningful change determination is an essential compo-
nent of clinical endpoint development. mHealth, immer-
sive and interactive technologies offer great potential in
the development of novel clinical endpoints that may
provide important insights into the assessment and
monitoring of health status. This includes applications
developed to measure health status, in addition to those
intended as interventions where any resulting longitudi-
nal changes may also be measured while using the tech-
nology application. However, the literature contains very
few examples of the estimation of meaningful change
associated with endpoints derived from mHealth and
interactive technologies, making the interpretability of
the impact of interventions measured using these technol-
ogies problematic. The approaches summarised in this
paper, however, are strongly recommended to be imple-
mented alongside application development. This can be
facilitated by early planning to include anchor measures
within pilot and validation studies to ensure the utility of
new clinical technology applications intended to measure
clinical change and solutions developed as interventions
to generate important changes in health status.
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